Serum thrombin‐activatable fibrinolysis inhibitor levels and its relation with pathogenesis and bleeding and prognosis in patients with Crimean Congo hemorrhagic fever

• Published in: Journal of medical virology Vol. 95; no. 1; pp. e28182 - n/a
• Main Authors: Altin, Nilgun, Altay, Fatma Aybala, Albayrak, Murat, Sahingoz, Seyda Ozdemir, Sencan, Irfan
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.01.2023
• Subjects: Adult; Bleeding; Carboxypeptidase B2; Coagulation; Crimean Congo hemorrhagic fever; Crimean hemorrhagic fever; Enzyme-linked immunosorbent assay; Fever; Fibrinolysis; Hemorrhage; Hemorrhagic Fever Virus, Crimean-Congo; Hemorrhagic Fever, Crimean - pathology; Humans; Immunoglobulin M; Infectious diseases; Inhibitors; Pathogenesis; Polymerase chain reaction; Prognosis; TAFI; Thrombin; viral hemorrhagic fever; Virology; viral hemorrhagic fever; bleeding; Crimean Congo hemorrhagic fever; prognosis; TAFI
• ISSN: 0146-6615; 1096-9071
• DOI: 10.1002/jmv.28182

Crimean‐Congo hemorrhagic fever (CCHF) is a viral hemorrhagic fever, which is common in Turkey and globally. The pathogenesis of coagulation disorders, which is seen in viral hemorrhagic fevers remains to be elucidated. Thrombin‐activatable fibrinolysis inhibitor (TAFI) has a key role in this process In this study, we aimed to evaluate whether TAFI levels contributed to bleeding and whether it is related to prognosis in CCHF patients. Eighty‐four patients older than 15 years of age, who were admitted to our hospital who had positive immunoglobulin M (enzyme‐linked immunosorbent assay [ELISA]) and/or polymerase chain reaction test results for CCHF between 2009 and 2010, were included in the study. The control group included 30 healthy adults. The plasma TAFI levels were compared between patients and controls, and also between patients with bleeding and no bleeding, and between patients with mild‐moderate and severe disease. The mean TAFI levels were lower in patients (mean: 87.82 ng/ml, median: 61.69 ng/ml (interquartile range [IQR] 30.49–537.95) than controls (mean: 313.5 ng/ml with a median: 338.5 ng/ml (IQR 182–418). However, median TAFI levels were significantly higher in patients with bleeding compared to those without bleeding (78.99 and 50.28 ng/ml, respectively; p = 0.032). Median IQR TAFI levels were similar between patients with mild‐moderate and severe disease (64.72 (41.37–113.85), and, 58.66 (42.44–118.93) ng/ml, respectively; p = 0.09) and survivors and nonsurvivors (86.14 ± 77.98 and 103.48 ± 69.92, respectively; p = 0.3). Although TAFI levels were lower in the patients with CCHF compared to healthy controls, it does not seem to be a major player in the prognosis.